Net Benefit of Anticoagulation in Subclinical Device-Detected Atrial Fibrillation
In this analytical model study, initiating NOACs in patients with device-detected subclinical AF was associated with a minimal increase in QALYs. However, the benefits were uncertain, and the effect size of the overall net benefit does not appear to be clinically meaningful.
Authors
- Konsta Teppo (ORCID: https://orcid.org/0000-0002-4460-0994)
- Juhani K.E. Airaksinen (ORCID: https://orcid.org/0000-0002-0193-568X)
- Ville L. Langén (ORCID: https://orcid.org/0000-0002-2382-7962)
- Aleksi K. Winstén
Institutions
- University of Turku (FI)
- Turku University Hospital (FI)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.8461
- Citations
- 8
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 11.11